【摘要】 目的评价奥沙利铂联合卡培他滨(XELOX)方案治疗晚期胃癌的疗效和不良反应。方法56例晚期胃癌患者予奥沙利铂130mg/m2,第1天,静脉滴注;卡培他滨1000mg/m2每天口服2次,第1～14天,21天为1个周期。至少治疗2周期评价疗效。结果CR0例,PR27例,SD13例,PD16例,总有效率为48.2%,疾病控制率(DCR)为71.4%。其中初治组总有效率为60.0%,明显高于复治组的34.6%(P<0.05)。不良反应主要为骨髓抑制、恶心呕吐、神经毒性。结论XELOX方案治疗晚期胃癌疗效肯定,安全性好,不良反应可耐受,值得临床进一步研究。更多还原

【Abstract】 Objective To investigate the efficacy and toxicity of oxaliplatin plus capecitabine(XELOX) chemotherapy in treatment of advanced gastric cancer (AGC).Methods 56 patients with advanced gastric cancer were treated with oxaliplatin 130 mg/m2intravenously on day 1 and oral capecitabine 1 000 mg/m2 twice a day from d1-14.The chemotherapy was repeated once every 3 weeks,and all patients received at least 2 cycles of chemotherapy.Results There was no complete response (CR).There were 27 partial response (PR),13 stable disease(SD) and 16 progress disease (PD).The overall response rate(RR) was 48.2%,and disease control rate(DCR) was 71.4%.The RR in initial treatment group was found more often than that in the retreatment group ( 60.0% Vs 34.6%,P<0.05).The main toxicities were myelosuppression,nausea,vomiting,and neutropenia.Conclusion Oxaliplatin plus capecitabine regimen is an effective and well tolerated treatment for AGC.It is worthy of further clinical research.更多还原